The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors, and fibrin architecture of a leukocyte- and platelet-rich fibrin (L-PRF) clot and membrane

Abstract L-PRF (leukocyte- and platelet-rich fibrin) is one of the four families of platelet concentrates for surgical use and is widely used in oral and maxillofacial regenerative therapies. The first objective of this article was to evaluate the mechanical vibrations appearing during centrifugation in four models of commercially available table-top centrifuges used to produce L-PRF and the impact of the centrifuge characteristics on the cell and fibrin architecture of a L-PRF clot and membrane. The second objective of this article was to evaluate how changing some parameters of the L-PRF protocol may influence its biological signature, independently from the characteristics of the centrifuge. In the first part, four different commercially available centrifuges were used to produce L-PRF, following the original L-PRF production method (glass-coated plastic tubes, 400 g force, 12 minutes). The tested systems were the original L-PRF centrifuge (Intra-Spin, Intra-Lock, the only CE and FDA cleared system for the preparation of L-PRF) and three other laboratory centrifuges (not CE/FDA cleared for L-PRF): A-PRF 12 (Advanced PRF, Process), LW-UPD8 (LW Scientific) and Salvin 1310 (Salvin Dental). Each centrifuge was opened for inspection, two accelerometers were installed (one radial, one vertical), and data were collected with a spectrum analyzer in two configurations (full-load or half load). All clots and membranes were collected into a sterile surgical box (Xpression kit, Intra-Lock). The exact macroscopic (weights, sizes) and microscopic (photonic and scanning electron microscopy SEM) characteristics of the L-PRF produced with these four different machines were evaluated. In the second part, venous blood was taken in two groups, respectively, Intra-Spin 9 ml glass-coated plastic tubes (Intra-Lock) and A-PRF 10 ml glass tubes (Process). Tubes were immediately centrifuged at 2700 rpm (around 400 g) during 12 minutes to produce L-PRF or at 1500 rpm during 14 minutes to produce A-PRF. All centrifugations were done using the original L-PRF centrifuge (Intra-Spin), as recommended by the two manufacturers. Half of the membranes were placed individually in culture media and transferred in a new tube at seven experimental times (up to 7 days). The releases of transforming growth factor β-1 (TGFβ-1), platelet derived growth factor AB (PDGF-AB), vascular endothelial growth factor (VEGF) and bone morphogenetic protein 2 (BMP-2) were quantified using ELISA kits at these seven experimental times. The remaining membranes were used to evaluate the initial quantity of growth factors of the L-PRF and A-PRF membranes, through forcible extraction. Very significant differences in the level of vibrations at each rotational speed were observed between the four tested centrifuges. The original L-PRF centrifuge (Intra-Spin) was by far the most stable machine in all configurations and always remained under the threshold of resonance, unlike the three other tested machines. At the classical speed of production of L-PRF, the level of undesirable vibrations on the original centrifuge was between 4.5 and 6 times lower than with other centrifuges. Intra-Spin showed the lowest temperature of the tubes. A-PRF and Salvin were both associated with a significant increase in temperature in the tube. Intra-Spin produced the heaviest clot and quantity of exudate among the four techniques. A-PRF and LW produced much lighter, shorter and narrower clots and membranes than the two other centrifuges. Light microscopy analysis showed relatively similar features for all L-PRF types (concentration of cell bodies in the first half). However, SEM illustrated considerable differences between samples. The original Intra-Spin L-PRF showed a strongly polymerized thick fibrin matrix and all cells appeared alive with a normal shape, including the textured surface aspect of activated lymphocytes. The A-PRF, Salvin and LW PRF-like membranes presented a lightly polymerized slim fibrin gel and most of the visible cell bodies appeared destroyed (squashed or shrunk). In the second part of this study, the slow release of the three tested growth factors from original L-PRF membranes was significantly stronger (more than twice stronger, p<0.001) at all experimental times than the release from A-PRF membranes. No trace of BMP2 could be detected in the A-PRF. A slow release of BMP2 was detected during at least 7 days in the original L-PRF. Moreover, the original L-PRF clots and membranes (produced with 9 mL blood) were always significantly larger than the A-PRF (produced with 10 mL blood). The A-PRF membranes dissolved in vitro after less than 3 days, while the L-PRF membrane remained in good shape during at least 7 days. Each centrifuge has its clear own profile of vibrations depending on the rotational speed, and the centrifuge characteristics are directly impacting the architecture and cell content of a L-PRF clot. This result may reveal a considerable flaw in all the PRP/PRF literature, as this parameter was never considered. The original L-PRF clot (Intra-Spin) presented very specific characteristics, which appeared distorted when using centrifuges with a higher vibration level. A-PRF, LW and Salvin centrifuges produced PRF-like materials with a damaged and almost destroyed cell population through the standard protocol, and it is therefore impossible to classify these products in the L-PRF family. Moreover, when using the same centrifuge, the original L-PRF protocol allowed producing larger clots/membranes and a more intense release of growth factors (biological signature at least twice stronger) than the modified A-PRF protocol. Both protocols are therefore significantly different, and the clinical and experimental results from the original L-PRF shall not be extrapolated to the A-PRF. Finally, the comparison between the total released amounts and the initial content of the membrane (after forcible extraction) highlighted that the leukocytes living in the fibrin matrix are involved in the production of significant amounts of growth factors. The centrifuge characteristics and centrifugation protocols impact significantly and dramatically the cells, growth factors and fibrin architecture of L-PRF.

[1]  T. Soukup,et al.  The VEGF and BMP-2 levels in patients with ankylosing spondylitis and the relationship to treatment with tumour necrosis factor alpha inhibitors. , 2014, Acta medica.

[2]  S. Ghanaati,et al.  Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. , 2014, The Journal of oral implantology.

[3]  D. M. Dohan Ehrenfest,et al.  Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. , 2014, Muscles, ligaments and tendons journal.

[4]  M. Endres,et al.  Bioactive Factors in Platelet-Rich Plasma Obtained by Apheresis , 2013, Transfusion Medicine and Hemotherapy.

[5]  Shenglin Ma,et al.  Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[6]  D. M. Dohan Ehrenfest,et al.  Leukocyte- and platelet-rich Plasma (L-PRP)/fibrin (L-PRF) in medicine - past, present, future. , 2012, Current pharmaceutical biotechnology.

[7]  D. M. Dohan Ehrenfest,et al.  Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). , 2012, Current pharmaceutical biotechnology.

[8]  A. Wiczkowski,et al.  The role of leukocytes from L-PRP/L-PRF in wound healing and immune defense: new perspectives. , 2012, Current pharmaceutical biotechnology.

[9]  D. M. Dohan Ehrenfest,et al.  Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 2: Bone graft, implant and reconstructive surgery. , 2012, Current pharmaceutical biotechnology.

[10]  G. Odin,et al.  L-PRP/L-PRF in esthetic plastic surgery, regenerative medicine of the skin and chronic wounds. , 2012, Current pharmaceutical biotechnology.

[11]  L. Rasmusson,et al.  In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. , 2012, Current pharmaceutical biotechnology.

[12]  D. M. Dohan Ehrenfest,et al.  Platelet-rich plasma (PRP) and Platelet-Rich Fibrin (PRF): surgical adjuvants, preparations for in situ regenerative medicine and tools for tissue engineering. , 2012, Current pharmaceutical biotechnology.

[13]  D. M. Dohan Ehrenfest,et al.  Current knowledge and perspectives for the use of platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in oral and maxillofacial surgery part 1: Periodontal and dentoalveolar surgery. , 2012, Current pharmaceutical biotechnology.

[14]  T. Bielecki,et al.  Editorials [Hot Topic: Leukocyte- and Platelet-Rich Plasma/Fibrin in Medicine – Past, Present, Future (Guest Editors: Tomasz Bielecki and David M. Dohan Ehrenfest)] , 2012 .

[15]  D. M. Dohan Ehrenfest,et al.  The use of leukocyte- and platelet-rich fibrin during immediate postextractive implantation and loading for the esthetic replacement of a fractured maxillary central incisor. , 2012, The Journal of oral implantology.

[16]  A. Lubkowska,et al.  Microbicidal properties of Leukocyte- and Platelet-Rich Plasma/Fibrin (L-PRP/L-PRF): new perspectives. , 2012, Journal of biological regulators and homeostatic agents.

[17]  D. M. Dohan Ehrenfest,et al.  Prevention of hemorrhagic complications after dental extractions into open heart surgery patients under anticoagulant therapy: the use of leukocyte- and platelet-rich fibrin. , 2011, The Journal of oral implantology.

[18]  M. Zumstein,et al.  The Future of Platelet Concentrates in Sports Medicine: Platelet-Rich Plasma, Platelet-Rich Fibrin, and the Impact of Scaffolds and Cells on the Long-term Delivery of Growth Factors , 2011 .

[19]  Bradley K Weiner,et al.  A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. , 2011, The spine journal : official journal of the North American Spine Society.

[20]  G. Sammartino,et al.  Simultaneous Sinus-Lift and Implantation Using Microthreaded Implants and Leukocyte- and Platelet-Rich Fibrin as Sole Grafting Material: A Six-Year Experience , 2011, Implant dentistry.

[21]  D. M. Dohan Ehrenfest,et al.  Shedding light in the controversial terminology for platelet-rich products: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), platelet-leukocyte gel (PLG), preparation rich in growth factors (PRGF), classification and commercialism. , 2010, Journal of biomedical materials research. Part A.

[22]  D. M. Dohan Ehrenfest,et al.  Selecting a relevant animal model for testing the in vivo effects of Choukroun's platelet-rich fibrin (PRF): rabbit tricks and traps. , 2010, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[23]  D. M. Dohan Ehrenfest,et al.  Selecting a relevant in vitro cell model for testing and comparing the effects of a Choukroun's platelet-rich fibrin (PRF) membrane and a platelet-rich plasma (PRP) gel: tricks and traps. , 2010, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[24]  D. M. Dohan Ehrenfest,et al.  Platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in human cell cultures: growth factor release and contradictory results. , 2010, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[25]  D. M. Ehrenfest,et al.  How to optimize the preparation of leukocyte- and platelet-rich fibrin (L-PRF, Choukroun's technique) clots and membranes: introducing the PRF Box. , 2010 .

[26]  D. M. Dohan Ehrenfest,et al.  Three-dimensional architecture and cell composition of a Choukroun's platelet-rich fibrin clot and membrane. , 2010, Journal of periodontology.

[27]  D. M. Dohan Ehrenfest,et al.  Choukroun's platelet-rich fibrin (PRF) stimulates in vitro proliferation and differentiation of human oral bone mesenchymal stem cell in a dose-dependent way. , 2010, Archives of oral biology.

[28]  D. M. Dohan Ehrenfest,et al.  Sinus floor augmentation with simultaneous implant placement using Choukroun's platelet-rich fibrin as the sole grafting material: a radiologic and histologic study at 6 months. , 2009, Journal of periodontology.

[29]  G. Odin,et al.  In vitro effects of Choukroun's PRF (platelet-rich fibrin) on human gingival fibroblasts, dermal prekeratinocytes, preadipocytes, and maxillofacial osteoblasts in primary cultures. , 2009, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[30]  D. M. Dohan Ehrenfest,et al.  The Relevance of Choukroun's Platelet-Rich Fibrin and Metronidazole During Complex Maxillary Rehabilitations Using Bone Allograft. Part II: Implant Surgery, Prosthodontics, and Survival , 2009, Implant dentistry.

[31]  D. M. Dohan Ehrenfest,et al.  The Relevance of Choukroun’s Platelet-Rich Fibrin and Metronidazole During Complex Maxillary Rehabilitations Using Bone Allograft. Part I: A New Grafting Protocol , 2009, Implant dentistry.

[32]  T. Albrektsson,et al.  Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). , 2009, Trends in biotechnology.

[33]  D. Etienne,et al.  Clinical evaluation of a modified coronally advanced flap alone or in combination with a platelet-rich fibrin membrane for the treatment of adjacent multiple gingival recessions: a 6-month study. , 2009, Journal of periodontology.

[34]  D. M. Dohan Ehrenfest,et al.  Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies , 2009, Growth factors.

[35]  M. Corso,et al.  Immediate implantation and peri-implant Natural Bone Regeneration (NBR) in the severely resorbed posterior mandible using Leukocyte- and Platelet-Rich Fibrin (L-PRF): a 4-year follow-up , 2013 .

[36]  Gilberto Sammartino,et al.  Guidelines for the publication of articles related to platelet concentrates (Platelet-Rich Plasma - PRP, or Platelet-Rich Fibrin - PRF): the international classification of the POSEIDO , 2013 .

[37]  D. M. Ehrenfest,et al.  The concept of Screw-Guided Bone Regeneration ( S-GBR ) . Part 3 : Fast Screw-Guided Bone Regeneration ( FS-GBR ) in the severely resorbed preimplant posterior mandible using allograft and Leukocyte-and Platelet-Rich Fibrin ( L-PRF ) : a 4-year follow-up , 2013 .

[38]  D. M. Ehrenfest,et al.  The concept of Screw-Guided Bone Regeneration (S-GBR). Part 2: S-GBR in the severely resorbed preimplant posterior mandible using bone xenograft and Leukocyte- and Platelet-Rich Fibrin (L-PRF): a 5-year follow-up , 2013 .

[39]  D. M. Dohan Ehrenfest How to optimize the preparation of leukocyte- and platelet-rich fibrin (L-PRF, Choukroun's technique) clots and membranes: introducing the PRF Box. , 2010, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[40]  D. M. Dohan Ehrenfest,et al.  Re: "Clinical evaluation of a modified coronally advanced flap alone or in combination with a platelet-rich fibrin membrane for the treatment of adjacent multiple gingival recessions: a 6-month study". , 2009, Journal of periodontology.